On Health Suites, AstraZeneca has signed a new purchase agreement with the government of Singapore to deliver Evusheld, its long-acting antibody (LAAB) combination candidate, for the treatment of COVID-19. With the supply expected to arrive in Singapore by year end, Claressa Monteiro speaks to Vinod Narayanan, Country President, AstraZeneca Singapore, to find out more about Evusheld.

Industry Insight: How AI is transforming the built environment
14:23

Industry Insight: How virtual twins are changing the way industries innovate
14:43

Industry Insight: The future of industrial real estate in Singapore
13:27